MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202441028355 A) filed by Nugenica Biotech Labs Private Limited, Chennai, Tamil Nadu, on April 5, 2024, for 'differentially expressed genes (degs) based novel process and kit for sepsis detection.'
Inventor(s) include Nugenica Biotech Labs Private Limited.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "The present invention provides a molecular diagnostic method for early detection of sepsis by parallel analysis of host gene expression and pathogen DNA. The method comprises: collecting a peripheral blood sample (100); isolating RNA and DNA (101); amplifying a defined panel of differentially expressed genes using SYBR Green-based real-time PCR in a DEG detection module (102) via a PCR unit (103); detecting microbial DNA using pathogen-specific primers targeting 16S rRNA and ITS regions in a pathogen identification module (104), stratified into Gram-positive (105), Gram-negative (106), and fungal (107) groups; and interpreting results using a diagnostic algorithm (108) to generate a sepsis diagnosis output (109). Relative gene expression is computed using the ??Ct method. The system enables risk stratification and sepsis classification without requiring fluorescent probes or specialized equipment."
Disclaimer: Curated by HT Syndication.
